NCT02214979已完成1 期
Bioequivalence of 40 mg Telmisartan / 2.5 mg Ramipril Fixed Dose Combination Compared With the Monocomponents, Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 84
- 主要终点
- Cmax (maximum measured concentration of the analyte in plasma)
研究概览
简要总结
Study to demonstrate the bioequivalence (BE) of 40 mg telmisartan/ 2.5 mg ramipril fixed-dose combination (FDC) versus its monocomponents given concomitantly
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females according to the following criteria based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
- •Age ≥18 and Age ≤55 years
- •BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial (especially unspecific inducing agents like St.John´s wort (Hypericum perforatum) or inhibitors like cimetidine) or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking during 24 hours prior to dosing and 24 hours after dosing
- •Alcohol abuse (more than 60 g/day) or inability to stop alcoholic beverages for 24 hours prior to dosing and up to the last sampling time point, 96 hours after dosing.
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- •A history of additional risk factors for torsade de pointes (e.g., heart failure, hyperkalemia, hypokalemia, family history of Long QT Syndrome)
- •Any history of relevant low blood pressure
- •Supine blood pressure at screening of systolic <110 mm Hg and diastolic <60 mm Hg
- •History of urticaria
- •History of angioneurotic edema
- •Hereditary fructose intolerance
- •For female subjects:
- •Pregnancy or planning to become pregnant during the study or within 2 months of study completion
- •Positive pregnancy test
- •Are not willing or are unable to use a reliable method of contraception (such as implants, injectables and combined oral contraceptives, sterilisation, intrauterine device, double barrier method, sexual abstinence) for at least 1 month prior to participation in the trial, during and up to 1 month after completion/termination of the trial
- •Chronic use of oral contraception or hormone replacement containing ethinyl estradiol as the only method of contraception
- •Currently lactating
研究组 & 干预措施
Telmisartan/Ramipril
Experimental
干预措施: Telmisartan/Ramipril (Drug)
Telmisartan + Ramipril capsule
Active Comparator
干预措施: Telmisartan (Drug)
Telmisartan + Ramipril capsule
Active Comparator
干预措施: Ramipril capsule (Drug)
Telmisartam + Ramipril tablet
Active Comparator
干预措施: Telmisartan (Drug)
Telmisartam + Ramipril tablet
Active Comparator
干预措施: Ramipril tablet (Drug)
结局指标
主要结局
Cmax (maximum measured concentration of the analyte in plasma)
时间窗: up to 96 hours after drug administration
AUC0-inf. (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
时间窗: up to 96 hours after drug administration
次要结局
- AUCt1-t2 (area under the concentration-time curve of the analyte in plasma over the time interval from t1 to t2)(up to 96 hours after drug administration)
- λz (terminal rate constant in plasma)(up to 96 hours after drug administration)
- tmax (time from dosing to the maximum concentration of the analyte in plasma)(up to 96 hours after drug administration)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 96 hours after drug administration)
- t1/2 (terminal half-life of the analyte in plasma)(up to 96 hours after drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 96 hours after drug administration)
- Number of patients with clinically relevant changes in 12-lead electrocardiogram(up to 73 days)
- MRTpo (mean residence time of the analyte in the body after po administration)(up to 96 hours after drug administration)
- CL/F (apparent clearance of the analyte in the plasma after extravascular administration)(up to 96 hours after drug administration)
- Number of patients with adverse events(up to 73 days)
- Number of patients with clinically relevant changes in Vital Signs (Blood Pressure, Pulse Rate)(up to 73 days)
- Number of patients with clinically relevant changes in laboratory tests(up to 73 days)
研究者
相似试验
已完成
1 期
Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female VolunteersHealthyNCT02214992Boehringer Ingelheim84
已完成
1 期
Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female VolunteersHealthyNCT02259829Boehringer Ingelheim84
已完成
1 期
Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female VolunteersHealthyNCT02193308Boehringer Ingelheim84
已完成
1 期
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant UseHealthyNCT01344629Boehringer Ingelheim64
已完成
1 期
Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male VolunteersHealthyNCT02263989Boehringer Ingelheim30